Global burden of multiple myeloma

A systematic analysis for the global burden of disease study 2016

Andrew J. Cowan, Christine Allen, Aleksandra Barac, Huda Basaleem, Isabela Bensenor, Maria Paula Curado, Kyle Foreman, Rahul Gupta, James Harvey, Howard D. Hosgood, Mihajlo Jakovljevic, Yousef Khader, Shai Linn, Deepesh Lad, Lorenzo Mantovani, Vuong Minh Nong, Ali Mokdad, Mohsen Naghavi, Maarten Postma, Gholamreza Roshandel & 10 others Katya Shackelford, Mekonnen Sisay, Cuong Tat Nguyen, Tung Thanh Tran, Bach Tran Xuan, Kingsley Nnanna Ukwaja, Stein Emil Vollset, Elisabete Weiderpass, Edward N. Libby, Christina Fitzmaurice

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

INTRODUCTION Multiplemyeloma (MM) is a plasma cell neoplasm with substantial morbidity and mortality. A comprehensive description of the global burden ofMMis needed to help direct health policy, resource allocation, research, and patient care. OBJECTIVE To describe the burden ofMMand the availability of effective therapies for 21 world regions and 195 countries and territories from 1990 to 2016. DESIGN AND SETTING We report incidence, mortality, and disability-Adjusted life-year (DALY) estimates from the Global Burden of Disease 2016 study. Data sources include vital registration system, cancer registry, drug availability, and survey data for stem cell transplant rates.We analyzed the contribution of aging, population growth, and changes in incidence rates to the overall change in incident cases from 1990 to 2016 globally, by sociodemographic index (SDI) and by region.We collected data on approval of lenalidomide and bortezomib worldwide. MAIN OUTCOMES AND MEASURES Multiplemyeloma mortality; incidence; years lived with disabilities; years of life lost; and DALYs by age, sex, country, and year. RESULTS Worldwide in 2016 there were 138 509 (95%uncertainty interval [UI], 121 000-155 480) incident cases ofMMwith an age-standardized incidence rate (ASIR) of 2.1 per 100 000 persons (95%UI, 1.8-2.3). Incident cases from 1990 to 2016 increased by 126% globally and by 106%to 192%for all SDI quintiles. The 3 world regions with the highest ASIR ofMMwere Australasia, North America, andWestern Europe. Multiplemyeloma caused 2.1 million (95%UI, 1.9-2.3 million) DALYs globally in 2016. Stem cell transplantation is routinely available in higher-income countries but is lacking in sub-Saharan Africa and parts of the Middle East. In 2016, lenalidomide and bortezomib had been approved in 73 and 103 countries, respectively. CONCLUSIONS AND RELEVANCE Incidence ofMMis highly variable among countries but has increased uniformly since 1990, with the largest increase in middle and low-middle SDI countries. Access to effective care is very limited in many countries of low socioeconomic development, particularly in sub-Saharan Africa. Global health policy priorities forMMare to improve diagnostic and treatment capacity in low and middle income countries and to ensure affordability of effective medications for every patient. Research priorities are to elucidate underlying etiological factors explaining the heterogeneity inmyeloma incidence.

Original languageEnglish (US)
Pages (from-to)1221-1227
Number of pages7
JournalJAMA oncology
Volume4
Issue number9
DOIs
StatePublished - Sep 1 2018

Fingerprint

Multiple Myeloma
Incidence
Uncertainty
Africa South of the Sahara
Health Policy
Mortality
Plasma Cell Neoplasms
Australasia
Health Priorities
Middle East
Quality-Adjusted Life Years
Resource Allocation
Health Resources
Information Storage and Retrieval
Population Growth
Stem Cell Transplantation
North America
Global Burden of Disease
Research
Registries

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Cowan, A. J., Allen, C., Barac, A., Basaleem, H., Bensenor, I., Curado, M. P., ... Fitzmaurice, C. (2018). Global burden of multiple myeloma: A systematic analysis for the global burden of disease study 2016. JAMA oncology, 4(9), 1221-1227. https://doi.org/10.1001/jamaoncol.2018.2128

Global burden of multiple myeloma : A systematic analysis for the global burden of disease study 2016. / Cowan, Andrew J.; Allen, Christine; Barac, Aleksandra; Basaleem, Huda; Bensenor, Isabela; Curado, Maria Paula; Foreman, Kyle; Gupta, Rahul; Harvey, James; Hosgood, Howard D.; Jakovljevic, Mihajlo; Khader, Yousef; Linn, Shai; Lad, Deepesh; Mantovani, Lorenzo; Nong, Vuong Minh; Mokdad, Ali; Naghavi, Mohsen; Postma, Maarten; Roshandel, Gholamreza; Shackelford, Katya; Sisay, Mekonnen; Nguyen, Cuong Tat; Tran, Tung Thanh; Xuan, Bach Tran; Ukwaja, Kingsley Nnanna; Vollset, Stein Emil; Weiderpass, Elisabete; Libby, Edward N.; Fitzmaurice, Christina.

In: JAMA oncology, Vol. 4, No. 9, 01.09.2018, p. 1221-1227.

Research output: Contribution to journalArticle

Cowan, AJ, Allen, C, Barac, A, Basaleem, H, Bensenor, I, Curado, MP, Foreman, K, Gupta, R, Harvey, J, Hosgood, HD, Jakovljevic, M, Khader, Y, Linn, S, Lad, D, Mantovani, L, Nong, VM, Mokdad, A, Naghavi, M, Postma, M, Roshandel, G, Shackelford, K, Sisay, M, Nguyen, CT, Tran, TT, Xuan, BT, Ukwaja, KN, Vollset, SE, Weiderpass, E, Libby, EN & Fitzmaurice, C 2018, 'Global burden of multiple myeloma: A systematic analysis for the global burden of disease study 2016', JAMA oncology, vol. 4, no. 9, pp. 1221-1227. https://doi.org/10.1001/jamaoncol.2018.2128
Cowan, Andrew J. ; Allen, Christine ; Barac, Aleksandra ; Basaleem, Huda ; Bensenor, Isabela ; Curado, Maria Paula ; Foreman, Kyle ; Gupta, Rahul ; Harvey, James ; Hosgood, Howard D. ; Jakovljevic, Mihajlo ; Khader, Yousef ; Linn, Shai ; Lad, Deepesh ; Mantovani, Lorenzo ; Nong, Vuong Minh ; Mokdad, Ali ; Naghavi, Mohsen ; Postma, Maarten ; Roshandel, Gholamreza ; Shackelford, Katya ; Sisay, Mekonnen ; Nguyen, Cuong Tat ; Tran, Tung Thanh ; Xuan, Bach Tran ; Ukwaja, Kingsley Nnanna ; Vollset, Stein Emil ; Weiderpass, Elisabete ; Libby, Edward N. ; Fitzmaurice, Christina. / Global burden of multiple myeloma : A systematic analysis for the global burden of disease study 2016. In: JAMA oncology. 2018 ; Vol. 4, No. 9. pp. 1221-1227.
@article{5480822d435c456e9ecd7bdc03476e68,
title = "Global burden of multiple myeloma: A systematic analysis for the global burden of disease study 2016",
abstract = "INTRODUCTION Multiplemyeloma (MM) is a plasma cell neoplasm with substantial morbidity and mortality. A comprehensive description of the global burden ofMMis needed to help direct health policy, resource allocation, research, and patient care. OBJECTIVE To describe the burden ofMMand the availability of effective therapies for 21 world regions and 195 countries and territories from 1990 to 2016. DESIGN AND SETTING We report incidence, mortality, and disability-Adjusted life-year (DALY) estimates from the Global Burden of Disease 2016 study. Data sources include vital registration system, cancer registry, drug availability, and survey data for stem cell transplant rates.We analyzed the contribution of aging, population growth, and changes in incidence rates to the overall change in incident cases from 1990 to 2016 globally, by sociodemographic index (SDI) and by region.We collected data on approval of lenalidomide and bortezomib worldwide. MAIN OUTCOMES AND MEASURES Multiplemyeloma mortality; incidence; years lived with disabilities; years of life lost; and DALYs by age, sex, country, and year. RESULTS Worldwide in 2016 there were 138 509 (95{\%}uncertainty interval [UI], 121 000-155 480) incident cases ofMMwith an age-standardized incidence rate (ASIR) of 2.1 per 100 000 persons (95{\%}UI, 1.8-2.3). Incident cases from 1990 to 2016 increased by 126{\%} globally and by 106{\%}to 192{\%}for all SDI quintiles. The 3 world regions with the highest ASIR ofMMwere Australasia, North America, andWestern Europe. Multiplemyeloma caused 2.1 million (95{\%}UI, 1.9-2.3 million) DALYs globally in 2016. Stem cell transplantation is routinely available in higher-income countries but is lacking in sub-Saharan Africa and parts of the Middle East. In 2016, lenalidomide and bortezomib had been approved in 73 and 103 countries, respectively. CONCLUSIONS AND RELEVANCE Incidence ofMMis highly variable among countries but has increased uniformly since 1990, with the largest increase in middle and low-middle SDI countries. Access to effective care is very limited in many countries of low socioeconomic development, particularly in sub-Saharan Africa. Global health policy priorities forMMare to improve diagnostic and treatment capacity in low and middle income countries and to ensure affordability of effective medications for every patient. Research priorities are to elucidate underlying etiological factors explaining the heterogeneity inmyeloma incidence.",
author = "Cowan, {Andrew J.} and Christine Allen and Aleksandra Barac and Huda Basaleem and Isabela Bensenor and Curado, {Maria Paula} and Kyle Foreman and Rahul Gupta and James Harvey and Hosgood, {Howard D.} and Mihajlo Jakovljevic and Yousef Khader and Shai Linn and Deepesh Lad and Lorenzo Mantovani and Nong, {Vuong Minh} and Ali Mokdad and Mohsen Naghavi and Maarten Postma and Gholamreza Roshandel and Katya Shackelford and Mekonnen Sisay and Nguyen, {Cuong Tat} and Tran, {Tung Thanh} and Xuan, {Bach Tran} and Ukwaja, {Kingsley Nnanna} and Vollset, {Stein Emil} and Elisabete Weiderpass and Libby, {Edward N.} and Christina Fitzmaurice",
year = "2018",
month = "9",
day = "1",
doi = "10.1001/jamaoncol.2018.2128",
language = "English (US)",
volume = "4",
pages = "1221--1227",
journal = "JAMA oncology",
issn = "2374-2437",
publisher = "American Medical Association",
number = "9",

}

TY - JOUR

T1 - Global burden of multiple myeloma

T2 - A systematic analysis for the global burden of disease study 2016

AU - Cowan, Andrew J.

AU - Allen, Christine

AU - Barac, Aleksandra

AU - Basaleem, Huda

AU - Bensenor, Isabela

AU - Curado, Maria Paula

AU - Foreman, Kyle

AU - Gupta, Rahul

AU - Harvey, James

AU - Hosgood, Howard D.

AU - Jakovljevic, Mihajlo

AU - Khader, Yousef

AU - Linn, Shai

AU - Lad, Deepesh

AU - Mantovani, Lorenzo

AU - Nong, Vuong Minh

AU - Mokdad, Ali

AU - Naghavi, Mohsen

AU - Postma, Maarten

AU - Roshandel, Gholamreza

AU - Shackelford, Katya

AU - Sisay, Mekonnen

AU - Nguyen, Cuong Tat

AU - Tran, Tung Thanh

AU - Xuan, Bach Tran

AU - Ukwaja, Kingsley Nnanna

AU - Vollset, Stein Emil

AU - Weiderpass, Elisabete

AU - Libby, Edward N.

AU - Fitzmaurice, Christina

PY - 2018/9/1

Y1 - 2018/9/1

N2 - INTRODUCTION Multiplemyeloma (MM) is a plasma cell neoplasm with substantial morbidity and mortality. A comprehensive description of the global burden ofMMis needed to help direct health policy, resource allocation, research, and patient care. OBJECTIVE To describe the burden ofMMand the availability of effective therapies for 21 world regions and 195 countries and territories from 1990 to 2016. DESIGN AND SETTING We report incidence, mortality, and disability-Adjusted life-year (DALY) estimates from the Global Burden of Disease 2016 study. Data sources include vital registration system, cancer registry, drug availability, and survey data for stem cell transplant rates.We analyzed the contribution of aging, population growth, and changes in incidence rates to the overall change in incident cases from 1990 to 2016 globally, by sociodemographic index (SDI) and by region.We collected data on approval of lenalidomide and bortezomib worldwide. MAIN OUTCOMES AND MEASURES Multiplemyeloma mortality; incidence; years lived with disabilities; years of life lost; and DALYs by age, sex, country, and year. RESULTS Worldwide in 2016 there were 138 509 (95%uncertainty interval [UI], 121 000-155 480) incident cases ofMMwith an age-standardized incidence rate (ASIR) of 2.1 per 100 000 persons (95%UI, 1.8-2.3). Incident cases from 1990 to 2016 increased by 126% globally and by 106%to 192%for all SDI quintiles. The 3 world regions with the highest ASIR ofMMwere Australasia, North America, andWestern Europe. Multiplemyeloma caused 2.1 million (95%UI, 1.9-2.3 million) DALYs globally in 2016. Stem cell transplantation is routinely available in higher-income countries but is lacking in sub-Saharan Africa and parts of the Middle East. In 2016, lenalidomide and bortezomib had been approved in 73 and 103 countries, respectively. CONCLUSIONS AND RELEVANCE Incidence ofMMis highly variable among countries but has increased uniformly since 1990, with the largest increase in middle and low-middle SDI countries. Access to effective care is very limited in many countries of low socioeconomic development, particularly in sub-Saharan Africa. Global health policy priorities forMMare to improve diagnostic and treatment capacity in low and middle income countries and to ensure affordability of effective medications for every patient. Research priorities are to elucidate underlying etiological factors explaining the heterogeneity inmyeloma incidence.

AB - INTRODUCTION Multiplemyeloma (MM) is a plasma cell neoplasm with substantial morbidity and mortality. A comprehensive description of the global burden ofMMis needed to help direct health policy, resource allocation, research, and patient care. OBJECTIVE To describe the burden ofMMand the availability of effective therapies for 21 world regions and 195 countries and territories from 1990 to 2016. DESIGN AND SETTING We report incidence, mortality, and disability-Adjusted life-year (DALY) estimates from the Global Burden of Disease 2016 study. Data sources include vital registration system, cancer registry, drug availability, and survey data for stem cell transplant rates.We analyzed the contribution of aging, population growth, and changes in incidence rates to the overall change in incident cases from 1990 to 2016 globally, by sociodemographic index (SDI) and by region.We collected data on approval of lenalidomide and bortezomib worldwide. MAIN OUTCOMES AND MEASURES Multiplemyeloma mortality; incidence; years lived with disabilities; years of life lost; and DALYs by age, sex, country, and year. RESULTS Worldwide in 2016 there were 138 509 (95%uncertainty interval [UI], 121 000-155 480) incident cases ofMMwith an age-standardized incidence rate (ASIR) of 2.1 per 100 000 persons (95%UI, 1.8-2.3). Incident cases from 1990 to 2016 increased by 126% globally and by 106%to 192%for all SDI quintiles. The 3 world regions with the highest ASIR ofMMwere Australasia, North America, andWestern Europe. Multiplemyeloma caused 2.1 million (95%UI, 1.9-2.3 million) DALYs globally in 2016. Stem cell transplantation is routinely available in higher-income countries but is lacking in sub-Saharan Africa and parts of the Middle East. In 2016, lenalidomide and bortezomib had been approved in 73 and 103 countries, respectively. CONCLUSIONS AND RELEVANCE Incidence ofMMis highly variable among countries but has increased uniformly since 1990, with the largest increase in middle and low-middle SDI countries. Access to effective care is very limited in many countries of low socioeconomic development, particularly in sub-Saharan Africa. Global health policy priorities forMMare to improve diagnostic and treatment capacity in low and middle income countries and to ensure affordability of effective medications for every patient. Research priorities are to elucidate underlying etiological factors explaining the heterogeneity inmyeloma incidence.

UR - http://www.scopus.com/inward/record.url?scp=85053397909&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053397909&partnerID=8YFLogxK

U2 - 10.1001/jamaoncol.2018.2128

DO - 10.1001/jamaoncol.2018.2128

M3 - Article

VL - 4

SP - 1221

EP - 1227

JO - JAMA oncology

JF - JAMA oncology

SN - 2374-2437

IS - 9

ER -